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“Neurocovid”: An Analysis of the 
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When SARS-CoV-2 began to spread, older adults experienced disproportionately 
greater adverse effects from the pandemic, including exacerbation of pre-existing 
physical and cognitive frailty conditions. More severe complications, higher mor-
tality, and concerns about disruptions to their daily routines and access to care. 
Knowledge about the impact of COVID-19 on the brain is rapidly accumulating and 
this is reflected in the increasing use of the term “neurocovid”. Co-involvement of the 
central and peripheral nervous system had already been observed in SARS patients, 
but COVID-19 seems to invade it with greater affinity than other coronaviruses. 
This chapter provides an overview of the expanding understanding of the multiple 
ways in which COVID-19 affects the human brain, discuss the likelihood of long-
term sequelae of neurocovid, and their implications for cognitive functions and 
behaviors in the elderly.
Keywords: COVID-19; SARS-CoV-2, neurocovid, long term pandemic fatigue, 
mechanisms of brain damage, brain dysfunction, neurology, neuropsychology, 
neuropsychiatry, cognitive dysfunctions, mood changes, anxiety, depression,  
social isolation, frailty, elderly, older adults
1. Introduction
Europe is a country that is getting older every day. An increasingly significant 
number of people find themselves in a condition of vulnerability and are at greater 
risk of suffering a functional loss and/or loss of autonomy [1, 2]. These conditions 
have been accentuated during the health emergency due to the current pandemic 
situation [3].
The elderly population has been burdened with a higher incidence and mortal-
ity of infection: the older adults have been shown to contract the infection in a 
more severe clinical form and this is especially true in Europe which, having, after 
Japan, the highest percentage of elderly people, has paid a very high toll in terms of 
mortality [3]. More than 95 per cent of the deaths involved people over the age of 
60, and 50 per cent of all deaths were aged ≥80 [4].
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The disease did not strike indiscriminately; it was mainly the elderly with 
serious concomitant chronic diseases (cardiovascular diseases, respiratory diseases, 
diabetes, neurodegenerative diseases, oncological diseases, etc.) who paid the 
highest price in terms of mortality [3, 4]. A particular incidence of fatal events 
has occurred among people living in social and health care residences throughout 
Europe [3, 4]. It is reasonable to assume that the virus has affected residential care 
facilities because of the community life that takes place there, affecting people 
already suffering from frailty and polypathology, so that the damage caused by the 
virus has been superimposed on that caused by coexisting diseases.
Considering the above, social distancing measures severely penalized the 
elderly, since they needed to be isolated as they could act as healthy carriers for 
the community and, if they became ill, would produce extraordinary pressure on 
intensive care [4].
The Covid-19 pandemic has also brought to light the concept that it is above 
all the frail elderly who are at high risk of functional, cognitive and psycho-social 
disabilities that make it difficult for the elderly to return to their pre-infection 
condition: this is the key to interpreting the relationship between the elderly and the 
coronavirus infection.
This inference is derived from what is observed about the global population. 
It seems increasingly likely that the majority of all those infected wills experience 
chronic sequelae of the disease, resulting in disability or diminished quality of life, 
a phenomenon now described as “long-covid” [5, 6]. Indeed, COVID-19 survivors 
can suffer from persistent symptoms after recovering [5], especially related to organ 
damage, post viral syndrome, and post-critical care syndrome [6]. Long-covid is 
characterized by breathlessness, chest tightness, cough, fatigue, myalgia, palpita-
tions, sleep disorders and difficulty to focus [5, 6]. Anxiety and depression were 
also reported [5].
The SARS-CoV-2 pandemic has rekindled attention on the possible neuroviru-
lence of this virus and the possible involvement of the central nervous system and 
peripheral nervous system [7, 8]. The spectrum of central and peripheral nervous 
systems disease in COVID-19 patients is much broader than previously thought. 
Some form of “neurocovid” appears to occur in up to 30% of positive patients. It 
is therefore a phenomenon that deserves to be carefully investigated and evalu-
ated when screening and monitoring short- and long-term patients, especially the 
elderly.
2. Aging, frailty, and COVID-19
Aging is a natural phenomenon involving a progressive physiological transfor-
mation of the human body and of neuropsychological and behavioral functions 
[1, 2]. The aging phenomenon, in addition to the growing quantitative data on the 
total population, is characterized by the different attributes that qualitatively char-
acterize this process and transition. In fact, elderly life is structured by different 
levels of independence and dependence of individuals with respect to both primary 
family networks and secondary networks of assistance and care [1, 2].
The conceptualization of frailty is presented as an attempt to define this het-
erogeneity of conditions. Frailty is a condition of marked vulnerability to adverse 
events caused by a reduction in the functional reserves of multiple systems of the 
body due to the aging process and chronic polypathology. It is a condition that 
represents a risk factor for disability, hospitalization, institutionalization, and 
death [1–3]. At first, frailty appeared in the literature with a distinctly bio-medical 
or clinical meaning [9], but in the last decade it has acquired bio-psycho-social 
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connotations as well as medical ones. Starting from the works of Gobbens et al. [10] 
and Van Campen [11], it is preferred to define frailty as a condition of vulnerability 
at a bio-psycho-social level. Today we prefer to speak of frailty in the plural. There 
are functional, cognitive, psycho-social, clinical, and - finally - economic frailty. 
These different dimensions interact together in moments of greatest difficulty. The 
definition of “frail elderly” therefore refers to a person who, faced with a stressful 
event -such as the SARS-CoV-2 pandemic - is unable to respond adequately, and 
therefore succumbs, with an increased risk of adverse events: mortality, disability 
and worsening of his/her general condition.
An increasingly significant number of older people are in a frail state, making 
this a hot topic. Physical and cognitive frailty have proved more useful than ever in 
understanding the impact of the SARS-CoV-2 pandemic on the elderly population 
and in guiding the principles of vaccine clinical trials [3]. Indeed, not only frail 
older people are particularly vulnerable to serious or life-threatening infections, but 
the age-related dysregulation of the immune system (due to immunosenescence and 
inflammaging) results in poorer responses to vaccination [3].
3.  Neurological presentations of COVID-19: the polyform entity of 
neurocovid
Psychiatric and neurological complications were reported during the SARS 
epidemic in 2003 [11].
Apart from depression, anxiety disorders and suicidal ideations, fear for 
survival, and fear of infecting others; across all timeframes, stigmatization, 
reduced quality of life, psychological distress, and posttraumatic stress symptoms 
were reported [11]. Moreover, cases of organic hallucinosis (visual and auditory 
hallucinations), deliriums of persecution, temporo-spatial disorientation and 
hypomanic disorder were reported. In some cases, these manifestations have been 
classified as secondary to steroid therapy. Isolated cases of fatal Coronavirus OC43 
encephalomyelitis in the face of little pulmonary involvement [12] and generalized 
tonic–clonic convulsion in patients with infection and cerebrospinal fluid positivity 
for SARS-CoV [13] have also been described.
Recent data suggesting that the COVID-19 virus also reaches the central nervous 
system [7, 8, 14]. It has been shown that (like SARS-CoV) COVID-19 virus exploits 
the receptor for the angiotensin converting enzyme 2 (ACE2) to enter cells. This 
discovery made it possible to investigate the expression of ACE2 in the neurological 
tissue and to determine the possible contribution of neurological tissue damage to 
morbidity and mortality caused by COVID-19 [7, 14].
The neuroinvasiveness, neurotropism and neurovirulence of the COVID-19 has 
been demonstrated [7]. Pathological studies suggest a direct route of neuroinva-
sion via haematogenous diffusion and retrograde transport by the olfactory nerve. 
Retrograde transport via the vagus and olfactory nerves remains hypothetical [7].
In most cases, COVID-19 would not make a direct attack on vulnerable struc-
tures. This would explain why various manifestations of the nervous system are 
favorable to immune suppression or immune modulation [8].
Direct affection of the central nervous system is uncommon and may result in 
meningitis/encephalitis [8, 15, 16], manifesting as headache, seizures, confusion, 
ataxia, pyramidal signs, or impaired consciousness. Direct affection of the periph-
eral nervous system includes hyposmia or hypogeusia [8].
Neurological disease due to the immune reaction against the COVID-19 
embraces acute disseminated encephalomyelitis; acute, haemorrhagic, myoclonus; 
necrotizing encephalopathy [17, 18]; cytokine release syndrome (a new nosographic 
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entity characterized by aphasia, behavioral alterations, central hypothyroidism, 
cerebellar ataxia, coma, confusion, cranial nerve palsy, dysautonomia, pyramidal 
signs, and tremor) and mononeuritis [19]; myositis [20]; cerebral vasculitis; 
delirium; psychosis; transverse myelitis [21]; cranial nerve palsy; Guillain-Barre 
syndrome [22]. Neurological long-term complications may be also secondary to 
affection of the heart or the kidneys [8]. Cardiac involvement may be responsible 
for cardioembolic, ischemic stroke, or ischemic stroke due to hypotension [8].
The COVID-19 pandemic continues to affect millions of people globally, 
with increasing reports of neurological manifestations but limited data on their 
incidence and associations with outcome. Two recent papers report the presence 
of neurological symptoms in 36.2% [23] and 80% [24] of patients hospitalized 
with COVID-19. Neurocovid is a polymorphic entity [25]. More than seventy 
different symptom combinations have been reported in the literature. Symptoms 
of a general nature seem to be present in almost all patients, often with abnormal 
laboratory tests [25]. The timing of symptoms varies from early states (anosmia, 
headache, myalgia) to later stages (altered mental status, neuromuscular disorders, 
seizures, stroke) [25]. Some neurological symptoms may persist (such as anos-
mia or headache), while others may cause persistent disability (such as stroke or 
polyneuropathy) [25].
4. Brain imaging findings and new classification system
The existence of alterations in brain structure as a result of SARS-CoV-2 infection 
appears to be well established [26, 27], even in subjects whose only symptom was 
anosmia [28]. Post-mortem structural MRI examinations revealed brain parenchy-
mal abnormalities, subcortical micro and macro hemorrhages, cortico-subcortical 
oedema, non-specific deep white matter changes and asymmetrical olfactory bulbs 
[29]. Similar evidence is also found in hospitalized patients [30–33]. The most com-
mon neuroimaging findings include cortical signal abnormalities on fluid-attenuated 
inversion recovery images, associated with leptomeningeal enhancement or cortical 
diffusion restriction [26], which may reflect autoimmune or infectious encephalitis, 
hypoglycaemia, hypoxia, or seizures [34]. Acute demyelinating lesions have also 
been depicted [35–38].
Starting from the observation that different neurobiological processes and 
mechanisms may lie behind the onset of neurocovid, a three-stage MRI classifica-
tion system to categorize patients has been recently proposed [39]:
• Neurocovid Stage 1: Viral damage is limited to epithelial cells of the nose and 
mouth with temporary loss of smell and taste.
• Neurocovid Stage 2: Inflammation floods from the lungs through the blood 
stream, leading to blood clots that prompt small and large strokes.
• Neurocovid Stage 3: The inflammation damages the blood–brain barrier. 
Inflammatory markers and viral particles infiltrate the brain, causing  
confusion, coma, encephalopathy, and seizures.
5. Aging, COVID-19, and neurocovid
Frailty elderly are more prone to cognitive impairment and SAR-CoV-2 
 infection [3]. Preexisting comorbidities (i.e., cerebrovascular, and cardiovascular 
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diseases, diabetes, hypertension, obesity, malignancy, and respiratory diseases) 
seem to be predictor of disease severity and neurological complications [40]. 
Moreover, elderly individuals with pre-existing neurological diseases are sus-
ceptible to more severe forms of COVID-19 infection and higher mortality rates 
[40, 41]. Indeed, it is now established that older people with Alzheimer’s and 
Parkinson’s diseases exhibit independent association with the rate of change 
in both physical frailty and cognitive impairment [42], placing these individu-
als at higher risk of COVID-19 disease severity [40]. Specifically, patients with 
Parkinson’s disease are vulnerable to infection due to advanced age, bulbar 
symptoms, respiratory dysfunction, frailty and cognitive impairment. Similarly, 
patients with Alzheimer’s disease and major neurocognitive disorder are at 
increased risk of infection and adverse events [43].
Elderly patients aged 65 years or older are known to have higher rates of neuro-
logical complications [40]. Commonly reported neurological dysfunctions include 
dizziness, confusion, fatigue, and headache. They may experience also atypical 
presentations such as falling or postural instability. Other neurological complica-
tions include cerebrovascular disease, cognitive impairment and neuropsychiatric 
disease [40]. Altered mental status and epilepsy have been also reported [25].
Older patients are particularly vulnerable to the psychological burden of 
COVID-19 [40]. Disturbed sleep, moderate to severe depression and anxiety have 
been reported [44]. Loneliness related to quarantine and social isolation has had 
a significant impact on mental health outcomes in the elderly [45], especially 
for those with chronic neurological diseases and neurocognitive disorder [46]. 
Quarantine comes to induce a rapid increase in behavioral and psychological symp-
toms in ~60% of patients and stress-related symptoms in two-thirds of caregivers 
[46]. The most common symptoms included agitation, anxiety, apathy, irritability, 
and sleep disturbances [46]. Similarly, a worsening of symptoms was observed in 
67.5% of Parkinson’s patients during the quarantine period [47].
6. Implications for neurocognitive and neuropsychiatric disorders
COVID-19 causes high levels of acute respiratory distress, hypoxia, and 
proinflammatory cytokines - all of which contribute to the onset of cognitive 
decline in the elderly [26]. It therefore seems reasonable that cardiovascular and 
cerebrovascular disease secondary to infection may contribute to an increased 
long-term risk of cognitive decline and major neurocognitive disorders in recov-
ered individuals [26, 48, 49].
After the SARS pandemics, one in five infected individuals reported memory 
problems [50]. Likewise, the current pandemic situation appears to have resulted 
in a dysexecutive syndrome in one in three individuals who have been hospitalized 
[50]. Poor memory, attention and speed of information processing impairments 
have commonly been reported with COVID-19 [39, 51].
This could lead to a vicious circle whereby impaired cognitive abilities may 
cause poor occupational and functional outcomes for individuals recovered from 
COVID-19 that precipitate or exacerbate mental health concerns, and poor mental 
health may likewise contribute to cognitive dysfunction [52].
Abnormalities in the mental status (defined as a severe change in personality, 
behavior, cognition, or consciousness) have been reported [39, 53], in line with 
what happened previously with the SARS pandemic [26]. COVID-19 patients 
experienced a high level of post-traumatic stress symptoms and a significantly 
higher level of depressive symptoms [39, 54]. In the post-illness phase, the point 
prevalence of post-traumatic stress disorder seems to be around 32%, depression 
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and anxiety disorder both around 15% [50]. Patients with pre-existing psychiatric 
disorders reported a worsening of their symptomatology [54].
Viral infections of the brain may have an impact on the risk of AD or Parkinson’s 
disease [26]. Olfactory deficits (hyposmia/anosmia) are among the sentinel 
symptoms of COVID-19 infection [55] and are characteristic of neurodegenerative 
disorders [56–58]. Indeed, anosmia is associated with high levels of interleukin-6, 
an inflammatory mediator causally implicated in brain disorders and which action 
is blocked by tocilizumab as part of COVID-19 treatment [59].
To date, the mechanisms by which neurological abnormalities result from 
SARS-CoV-2 infection have yet to be fully established. Nevertheless, the contribu-
tion resulting from direct effects of SARS-CoV-2 on neuronal function and survival 
or glial reactivity, exaggerated cytokine responses or anti-neuronal antibodies are 
all likely, as are sequelae of cerebrovascular accidents [26]. The data available to 
date suggest an increase in neuropsychiatric and neuropsychological long-term 
sequelae, including cognitive decline, motor impairment, and affective and psy-
chotic disorders [26].
7. Management and treatment of neurocovid in elderly patients
Treatment of neurocovid is currently based on existing evidence-based treatment 
for specific neurologic conditions in conjunction with systemic treatment of COVID-19 
infection (i.e., antivirals, corticosteroids, and immunomodulators) [25, 40].
The contagion is associated with neuropsychiatric symptoms [60] and it is 
recommended to set up a baseline mental status examination for all hospitalized 
COVID-19 old patients [61].
Delirium management has long been a priority in the care of older adults [25]. 
Every hospitalized older person should be considered at high risk for developing 
delirium, and prevention should be optimized [58]. Non-pharmacologic interven-
tions include patient-centered care with adequate hydration and sleep, optimiza-
tion of hearing and vision, early mobilization, frequent re-orientation, reduction 
of social isolation and regular visits, connecting patients with their families, and 
minimization of unnecessary lines, tubes, polypharmacy, and precipitating medi-
cations [61, 62]. Low-potency neuroleptics and alpha-2 adrenergic agents may be 
useful [60].
Neurologists, geriatricians and neuropsychologists must be involved at an early 
stage and be prepared to handle the peculiarities of neurocovid. It is advisable to 
have patients undergo neuropsychological assessment even 6–8 months after their 
discharge from hospital, especially if cognitive problems, slowness in processing 
information or poor attention persist [39].
Patients with below cut-off test scores should be evaluated for rehabilitation and 
cognitive enhancement interventions. This would reduce the risk of facilitating an 
earlier/rapid age-related cognitive decline [3, 39].
8. Conclusions
The high probability of long-term neurological and neuropsychological con-
sequences of COVID-19 indicates the importance of continuous surveillance for 
neuroimmune and neurodegenerative disorders in infected individuals, especially 
the elderly [7]. Until an effective treatment is discovered, or the expected global 
population-wide vaccination coverage is achieved, clinicians need to be alert to 
neurocovid [25].
7




1 European Innovation Partnership on Active and Healthy Ageing,  
Brussels, Belgium
2 Diagnostic and Technology Department, Neuroradiology Unit, Neurological 
Institute “Carlo Besta” IRCCS Foundation, Milan, Italy
*Address all correspondence to: sara.palermo@istituto-besta.it
Researchers have postulated several explanations for the severity with which 
COVID-19 occurs in the elderly and the increased mortality rate in this population 
group. Age-related epigenetic changes, inflammasome activity, covalent modifica-
tions of human and viral proteins, etc. are all possibilities currently being explored 
by scientists [63]. Future research will lead to a full understanding of the key factors 
leading to the vulnerability of the elderly population, especially about the intersec-
tion of aging, vulnerability to infection and alterations in cognitive-behavioral 
patterns. A neurocognitive approach could prove extremely useful for this purpose. 
It seems particularly appropriate to deepen our knowledge of the deleterious effects 
of SARS-CoV-2 and COVID-19 infection on the central and peripheral nervous 
system (in both structural and functional terms), and to assess through predictive 
medicine how these effects may contribute to the chronic burden of disease in the 
coming years. Notably, key questions need to be answered about the impact of the 
risk of cognitive decline in old age, Alzheimer’s disorder, Parkinson’s disorder and 
other neurodegenerations. In addition, a change of pace in the observation of the 
various conditions of elderly life can make it possible to construct complementary 
health and welfare interventions that have the characteristic of elasticity and 
immediacy to be placed alongside the traditional ones - above all in response to 
phenomena such as neurocovid.
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